There is no such thing as a serious anti-cyclic citrullinated peptide antibody of 300 RU/ml, the severity of which generally depends on whether or not there is a combination of rheumatoid arthritis and the severity of the rheumatoid arthritis.
The normal value of anti-cyclic citrullinated peptide antibody is less than 5 RU/ml, which has high sensitivity and specificity for diagnosing rheumatoid arthritis, and is a specific indicator for diagnosing the early stage of rheumatoid arthritis. Patients with anti-cyclic citrullinated peptide antibodies of 300 RU/ml need to first consider the possibility of rheumatoid arthritis.
Anti-cyclic citrullinated peptide antibodies can appear early in the disease and correlate with disease prognosis. Patients with positive anti-cyclic citrullinated peptide antibodies are more likely to develop joint damage than those with negative anti-cyclic citrullinated peptide antibodies.
The diagnosis of rheumatoid arthritis and the severity of rheumatoid joints need to be evaluated in conjunction with other clinical tests, such as rheumatoid factor, C-reactive protein, and blood sedimentation, as well as X-ray or ultrasound results.
If the anti-cyclic citrullinated peptide antibody is found to be elevated, it is recommended to consult the rheumatology and immunology department of a regular hospital for regular treatment under the guidance of a doctor.